MX2024004563A - Complejo polipeptidico activable. - Google Patents

Complejo polipeptidico activable.

Info

Publication number
MX2024004563A
MX2024004563A MX2024004563A MX2024004563A MX2024004563A MX 2024004563 A MX2024004563 A MX 2024004563A MX 2024004563 A MX2024004563 A MX 2024004563A MX 2024004563 A MX2024004563 A MX 2024004563A MX 2024004563 A MX2024004563 A MX 2024004563A
Authority
MX
Mexico
Prior art keywords
polypeptide complex
activatable polypeptide
activatable
hbpcs
egfr
Prior art date
Application number
MX2024004563A
Other languages
English (en)
Spanish (es)
Inventor
Raffaella Briante
Jennitte Leann Stevens
W Michael Kavanaugh
Ellaine Anne Mariano Fox
Sayantan Mitra
Madan M Paidhungat
Leila M Boustany
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2024004563A publication Critical patent/MX2024004563A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024004563A 2021-10-15 2022-10-14 Complejo polipeptidico activable. MX2024004563A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256410P 2021-10-15 2021-10-15
US202263370895P 2022-08-09 2022-08-09
PCT/US2022/078157 WO2023064927A1 (en) 2021-10-15 2022-10-14 Activatable polypeptide complex

Publications (1)

Publication Number Publication Date
MX2024004563A true MX2024004563A (es) 2024-04-30

Family

ID=84331755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004563A MX2024004563A (es) 2021-10-15 2022-10-14 Complejo polipeptidico activable.

Country Status (17)

Country Link
US (1) US20230183382A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539650A (cg-RX-API-DMAC7.html)
KR (1) KR20240115809A (cg-RX-API-DMAC7.html)
CN (1) CN118103405A (cg-RX-API-DMAC7.html)
AU (1) AU2022365116A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006111A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240204A (cg-RX-API-DMAC7.html)
IL (1) IL312145A (cg-RX-API-DMAC7.html)
JO (1) JOP20240086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004563A (cg-RX-API-DMAC7.html)
PE (1) PE20241343A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330611A (cg-RX-API-DMAC7.html)
UY (1) UY39984A (cg-RX-API-DMAC7.html)
WO (1) WO2023064927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496816A1 (en) * 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
JP2024539650A (ja) 2024-10-29
CN118103405A (zh) 2024-05-28
CL2024001180A1 (es) 2024-10-04
PE20241343A1 (es) 2024-07-03
US20230183382A1 (en) 2023-06-15
IL312145A (en) 2024-06-01
CO2024006111A2 (es) 2024-06-27
CR20240204A (es) 2024-09-13
EP4416180A1 (en) 2024-08-21
WO2023064927A9 (en) 2024-05-16
KR20240115809A (ko) 2024-07-26
WO2023064927A1 (en) 2023-04-20
CA3234609A1 (en) 2023-04-20
UY39984A (es) 2023-07-31
AU2022365116A1 (en) 2024-05-02
TW202330611A (zh) 2023-08-01
JOP20240086A1 (ar) 2024-04-14

Similar Documents

Publication Publication Date Title
MX2024004564A (es) Complejo polipeptidico activable.
JOP20240086A1 (ar) معقد بولي ببتيد قابل للتنشيط
MY199655A (en) Dll3-cd3 bispecific antibodies
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
WO2022175255A3 (en) Trispecific antibody targeting bcma, gprc5d, and cd3
AU2018337142A8 (en) Novel bispecific CD3/CD19 polypeptide complexes
JOP20210233A1 (ar) علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
PH12019500550A1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
SG10201900015XA (en) Bispecific cd33 and cd3 binding proteins
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
MX2023014905A (es) Terapias basadas en il2 y metodos de uso de las mismas.
EP4585611A3 (en) Proteins binding nkg2d, cd16 and egfr
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
ZA202305072B (en) Cd1a antibodies and uses thereof
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
WO2022232044A3 (en) Anti-clec12a antibodies and uses thereof
MY204320A (en) Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2024005683A (es) Anticuerpos contra el factor de necrosis tumoral alfa humano.